Clinical Trials Logo

Filter by:
NCT ID: NCT04535505 Withdrawn - Pertussis Clinical Trials

Pathogenic Bordetella Rapid Detection

Start date: July 2022
Phase:
Study type: Observational

A CPA platform based on the CRISPR technology is going to established to achieve the goal of detecting pathogenic bordetella and drug resistance genes in one step. The accuracy of this platform will be checked through prospective diagnostic test evaluation methods. Bordetella pertussis isolation culture and identification would be set as a gold standard method.

NCT ID: NCT04531865 Withdrawn - Clinical trials for Steroid-Dependent Nephrotic Syndrome

Randomized Trial Evaluating Mycophenolate Mofetil in Children With Nephrotic Syndrome After Rituximab Treatment

Start date: January 1, 2021
Phase: Phase 3
Study type: Interventional

The aim of this study is to evaluate the efficacy and safety of maintenance Mycophenolate Mofetil following single course of Rituximab in maintaining remission over 12 months among Children with frequently-relapsing or steroid-dependent nephrotic syndrome

NCT ID: NCT04531839 Withdrawn - Morality Clinical Trials

Improving Outcome of Very Preterm Infants Using Collaborative Quality Improvement

Start date: October 1, 2024
Phase: N/A
Study type: Interventional

A multicenter interventional study using evidence-based collaborative quality improvement to reduce mortality and major morbidities of very preterm infants in six neonatal centers in Shanghai

NCT ID: NCT04531397 Withdrawn - Clinical trials for Chronic Kidney Diseases

Efficacy and Safety of Dapagliflozin in Children With Proteinuric Chronic Kidney Disease

Start date: January 1, 2021
Phase: Phase 4
Study type: Interventional

We aim to investigate the antiproteinuric effect of adding Dapagliflozin to the standard of care in children with proteinuria.

NCT ID: NCT04529603 Withdrawn - Lung Neoplasm Clinical Trials

The Efficacy of Intraoperative Pulmonary Nodules Localization Guided by Virtual Reality Technology

Start date: December 1, 2020
Phase: N/A
Study type: Interventional

As the detection of small pulmonary nodules continuously grows, the intraoperative localization of small pulmonary nodules is in great demand. The intraoperative localization nowadays is usually done under local anesthesia before surgery. There is a certain rate of failure and complication. The result of our early animal experiments show that the pulmonary surgery marker system can deliver the intraoperative localization safely and precisely under anesthesia, and the average distance between the localization and the simulated lesion is less than 5mm during surgery. Therefore, the safety and feasibility of the system require further evaluation in patients

NCT ID: NCT04500795 Withdrawn - Clinical trials for Chronic Subdural Hematoma

Prospective Study on the Use of Middle Meningeal Artery Embolization for Chronic Subdural Haematoma

Start date: January 1, 2024
Phase: N/A
Study type: Interventional

Subdural haematoma is a common neurosurgical condition that results in different levels of neurological deficits in patients. It can be further classified into acute and chronic, which have different pathophysiology. Acute haematoma is a common result of traumatic injuries involving the tearing of the bridging veins, while chronic subdural haematoma can be both a result of traumatic injuries or recurrence following surgical management of the acute counterpart. For symptomatic patients, they are often surgically managed by haematoma drainage via burr-hole drainage and craniotomy. Recurrent bleeding following close monitor or surgical evacuation of haematoma is however very high. Recent studies approximate the recurrence rate of 2%-33.3%. Recent evidence suggests the angiogenesis of middle meningeal arteries (MMA) in response to inflammation and healing process contributes to the development of chronic subdural haematoma, and its high recurrence chance. Several studies have looked into the use of middle meningeal artery embolization to halt the bleeding of a chronic subdural haematoma, and have found promising results in terms of haematoma reduction and prevention of surgical rescues.

NCT ID: NCT04465734 Withdrawn - Clinical trials for Hepatocellular Carcinoma (HCC)

A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC

Start date: November 15, 2022
Phase: Phase 3
Study type: Interventional

This study is a randomized, double-blind, multicenter, phase III clinical study to compare the efficacy and safety of HLX10 + HLX04 vs Sorafenibas as the First-line Treatment in Patients with Locally Advanced or Metastatic HCC Eligible subjects in this study will be randomized to Arm A or Arm B at 2:1 ratio as follows: Arm A (treatment group): HLX10 + HLX04 Arm B (control group): sorafenib Randomization is stratified by: region (Asia (excluding Japan) vs. others), HBV infection vs. HCV infection vs. no HBV or HCV infection, portal vein invasion or/and extrahepatic spread (with vs.without), and ECOG (0 vs. 1).

NCT ID: NCT04447443 Withdrawn - Clinical trials for Chemotherapy-related Diarrhea

Impact of Dietary Fiber as Prebiotics on Chemotherapy-related Diarrhea in Patients With Gastrointestinal Tumors

Start date: June 30, 2020
Phase: N/A
Study type: Interventional

This study evaluates longitudinal data associating changes in gut microbiota composition and diversity, defecation, performance status and adverse reactions in response to prebiotic fiber supplementation in patients with gastrointestinal cancer chemotherapy-related diarrhea. 120 adult participants , age 18 to 65 years, will be randomized into one of the two arms. Arm A (intervention group) will receive prebiotic fiber and loperamide hydrochloride capsule(a drug for standard treatment). Arm B will receive maltodextrin placebo and loperamide hydrochloride capsule.

NCT ID: NCT04438473 Withdrawn - Enteral Nutrition Clinical Trials

Pectin Supplemented Enteral Feedings in Critically Ill Patients

Start date: July 30, 2020
Phase: N/A
Study type: Interventional

The current study will enroll critically ill patients who are going to require enteral nutrition support and randomize them to standard formula enteral nutrition or pectin-supplemented enteral nutrition in 7 days. The occurrence of enteral nutrition-related complications will be recorded and compared between groups. The study is trying to assess whether the use of pectin will improve the enteral nutrition-related complications in critically ill patients.

NCT ID: NCT04398927 Withdrawn - Metastatic Cancer Clinical Trials

Systemic Chemotherapy Plus PD-1 for Metastasis ICC

Start date: May 1, 2020
Phase: Phase 2
Study type: Interventional

This study were designed to verify the better method of survival for metastatic ICC. Since the traditional method for metastatic ICC was GEMOX(recommended from NCCN guideline), our previous study found better results from Folfirinox over GEMOX. Our current study were conducted for further investigation to verify the better method for metastatic ICC.